This study, called the Maternal Newborn Health Registry, aims to understand trends in pregnancy outcomes in areas with limited resources. Researchers are collecting information to learn more about stillbirths, and deaths of mothers and newborns. There is no specific intervention being tested in the main study. However, a sub-study related to COVID-19 will ask participants to provide a blood sample around the time of delivery to check for COVID-19 antibodies. This will help researchers understand how common COVID-19 is among pregnant women and its connection to pregnancy outcomes. You may be able to join if you are a pregnant woman planning to deliver within a study community. The study will be considered successful if it can accurately measure rates of maternal death (up to 42 days after delivery), stillbirths (at delivery), and early newborn deaths (up to 28 days after delivery). The current status of this study is unclear.

Study design

This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to include a large number of participants, around 950,000.

What's involved

If you join the COVID sub-study, you will be asked to provide a blood sample of about 3-5 cc at or near delivery (at delivery or up to 14 days after).

Compensation

Not stated in the trial record.

Follow-up

Maternal mortality is measured at 42 days post delivery, and early neonatal mortality is measured at 28 days post delivery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.